Clinical Trial Update: EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating EGFRBi-armed autologous T cells for adult brain glioblastoma and gliosarcoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• EGFRBi-armed autologous T cells

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Adult Brain Glioblastoma, Adult Gliosarcoma | Phase 1, Phase 2 | Status: WITHDRAWN